{"query":"Boundless Bio Zachary Hornby extrachromosomal DNA oncogene news","follow_up_questions":null,"answer":null,"images":[],"results":[{"url":"https://finance.yahoo.com/news/boundless-bio-participate-guggenheim-emerging-120000138.html","title":"Boundless Bio to Participate in the Guggenheim Emerging Outlook","content":"- Best Valentine's Day gifts. - Valentine's Day gifts for her. - Valentine's Day gifts for him. - Best high-yield savings accounts. ### New on Yahoo. # Yahoo Finance. This is a paid press release. Contact the press release distributor directly with any inquiries. SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Zachary Hornby, President and Chief Executive Officer, will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026. Boundless Bio is a clinical-stage oncology company dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors. Boundless Bio’s research focuses on extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in 14% to 17% of cancer patients. Boundless Bio is developing BBI-940, a potentially first-in-class orally bioavailable, selective Kinesin degrader as an ecDNA-directed therapeutic candidate (ecDTx).","score":0.90432173,"raw_content":null},{"url":"https://www.globenewswire.com/news-release/2025/05/23/3087713/0/en/Boundless-Bio-Announces-Portfolio-Prioritization-and-Runway-Extension.html","title":"Boundless Bio Announces Portfolio Prioritization and Runway","content":"Boundless Bio's research focuses on extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in 14% to 17% of cancer","score":0.78749067,"raw_content":null},{"url":"https://investors.boundlessbio.com/news-releases/news-release-details/boundless-bio-advances-novel-kinesin-degrader-program-bbi-940","title":"Boundless Bio Advances Novel Kinesin Degrader Program BBI-940 ...","content":"Boundless Bio's research focuses on extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in 14% to 17% of cancer","score":0.73914057,"raw_content":null},{"url":"https://investors.boundlessbio.com/news-releases/news-release-details/boundless-bio-participate-guggenheim-emerging-outlook-biotech","title":"Boundless Bio to Participate in the Guggenheim Emerging Outlook","content":"Boundless Bio's research focuses on extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in 14% to 17% of cancer","score":0.7336813,"raw_content":null},{"url":"https://timmermanreport.com/2024/09/boundless-bio-takes-on-cancer-drug-resistance-zach-hornby-on-the-long-run/","title":"Boundless Bio Takes on Oncogene Amplified Cancers: Zach Hornby ...","content":"It is developing small molecule drugs that take aim at DNA that resides outside the usual home on a chromosome. Zach Hornby, CEO, Boundless Bio.","score":0.7316155,"raw_content":null}],"response_time":1.1,"request_id":"be58cfcc-8a7b-4ac9-b3f9-a7eb19d028eb"}